BioTech Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s DiseaseBy Marie JonesMarch 14, 20250 Interim Analysis Expected End of 2Q 2025 Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company…
